Physician

Susmitha Apuri, M.D

According to 2025 Medicare claims, Susmitha Apuri, M.D (NPI: 1154598068) practices hematology/oncology in the Homosassa Springs, FL market, with the plurality of this provider's patient population coming from Citrus, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34461-9187. Apuri is affiliated with the Florida Medical Clinic ACO, LLC (ACO ID: A1131), participating under the MSSP model.

Apuri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,494 traditional Medicare patients, billed 385,301 HCPCS/CPT codes, and received $6,458,978 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,741 prescription claims across 390 beneficiaries totaling $5,339,551 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2022 DME data shows 25 claims. Open Payments data shows 129 records totaling $2,783. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $43,780 to $6,458,978. Similarly, Part D prescription costs have moved sharply higher in recent years, from $641 to $5,339,551. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	106	5,579	$43,780
2018	306	50,039	$469,001
2019	655	102,132	$1,214,530
2020	585	225,846	$2,524,153
2021	624	212,001	$2,405,692
2022	1,166	301,783	$3,450,083
2023	1,258	365,237	$4,620,368
2024	1,494	385,301	$6,458,978

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	14	22	$641
2016	21	29	$3,812
2017	16	36	$18,441
2018	83	345	$192,431
2019	145	504	$627,071
2020	132	610	$888,902
2021	137	703	$1,653,936
2022	196	924	$2,504,339
2023	289	1,266	$3,473,122
2024	390	1,741	$5,339,551

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	25	$1,169
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	587	1,961	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	536	964	$66
96372	Injection of drug or substance under skin or into muscle	389	1,041	$10
36415	Insertion of needle into vein for collection of blood sample	1,262	4,016	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,229	3,988	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	73	2,190	$1,057,692
Revlimid	Lenalidomide	49	1,253	$795,470
Ibrance	Palbociclib	28	784	$422,378
Sprycel	Dasatinib	21	630	$342,556
Cabometyx	Cabozantinib S-Malate	13	390	$323,924

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	129	$2,783	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Susmitha Apuri, M.D?

Tedicare shows public-source Medicare data for Susmitha Apuri, M.D (NPI 1154598068), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Susmitha Apuri, M.D have ACO affiliation data?

Susmitha Apuri, M.D is shown with ACO affiliation data for Florida Medical Clinic ACO, LLC (MSSP, ACO ID A1131).

What billing organization is linked to Susmitha Apuri, M.D?

Susmitha Apuri, M.D is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Susmitha Apuri, M.D have Open Payments data?

Susmitha Apuri, M.D has 129 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.